Disease · MONDO_0007739
Comparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 28
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A - Coenzyme Q10 2400 mg/Day vs B - Placebo: serious adverse events | 76 of 303 | 83 of 306 | 609 | NCT00608881 | Trial comparisons |
| Pridopidine vs Placebo: deaths from any cause | 4 of 250 | 1 of 249 | 499 | NCT04556656 | Trial comparisons |
| Pridopidine vs Placebo: serious adverse events | 34 of 250 | 21 of 249 | 499 | NCT04556656 | Trial comparisons |
| SAGE-718 vs Placebo: deaths from any cause | 0 of 95 | 0 of 94 | 189 | NCT05107128 | Trial comparisons |
| SAGE-718 vs Placebo: serious adverse events | 3 of 95 | 6 of 94 | 189 | NCT05107128 | Trial comparisons |
| Cohort 1 (Direct Rollover) vs Cohort 2 (Gap Rollover): Number of Participants Who Withdrew From Study Due to TEAEs | 2 of 72 | 3 of 81 | 153 | NCT05655520 | Trial comparisons |
| Cohort 1 (Direct Rollover) vs Cohort 2 (Gap Rollover): deaths from any cause | 0 of 72 | 0 of 81 | 153 | NCT05655520 | Trial comparisons |
| Cohort 1 (Direct Rollover) vs Cohort 2 (Gap Rollover): Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | 46 of 72 | 46 of 81 | 153 | NCT05655520 | Trial comparisons |
| Cohort 1 (Direct Rollover) vs Cohort 2 (Gap Rollover): serious adverse events | 3 of 72 | 6 of 81 | 153 | NCT05655520 | Trial comparisons |
| Rollover Cohort: SD-809 ER vs Switch Cohort: SD-809 ER: deaths from any cause | 1 of 82 | 0 of 37 | 119 | NCT01897896 | Trial comparisons |
| Rollover Cohort: SD-809 ER vs Switch Cohort: SD-809 ER: serious adverse events | 21 of 82 | 11 of 37 | 119 | NCT01897896 | Trial comparisons |
| Minocycline 100 mg Twice Daily vs Matching Placebo Twice Daily: serious adverse events | 11 of 87 | 1 of 27 | 114 | NCT00277355 | Trial comparisons |
| SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy Based on Clinical Global Impression of Change (CGIC) | 19 of 45 | 6 of 45 | 90 | NCT01795859 | Trial comparisons |
| SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC) | 23 of 45 | 9 of 45 | 90 | NCT01795859 | Trial comparisons |
| SD-809 vs Placebo: serious adverse events | 1 of 45 | 1 of 45 | 90 | NCT01795859 | Trial comparisons |
| Pridopidine 45 mg BID vs Placebo: Total Functional Capacity Responder Rate in Early HD | 30 of 37 | 20 of 41 | 78 | NCT02006472 | Trial comparisons |
| RO7234292 Monthly vs RO7234292 Bimonthly: deaths from any cause | 1 of 23 | 0 of 23 | 46 | NCT03342053 | Trial comparisons |
| RO7234292 Monthly vs RO7234292 Bimonthly: serious adverse events | 4 of 23 | 3 of 23 | 46 | NCT03342053 | Trial comparisons |
| Atomoxetine vs Matching Placebo: serious adverse events | 0 of 20 | 3 of 20 | 40 | NCT00368849 | Trial comparisons |
| SAGE-718 vs Placebo: Number of Participants With HD With Clinically Significant Change From Baseline in Vital Sign Measurements | 0 of 21 | 0 of 19 | 40 | NCT05358821 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007739/comparisons